What is the clinical evidence from this study?

Population: Normal myocardium (in vitro). Intervention: EGIS-7229 vs. Dofetilide (30 and 100 nM). Primary outcome: Effective refractory period (ERP) prolongation at 2 Hz stimulation rate in hypokalemia (p=<0.05).

January 1, 2006Journal of Pharmacological SciencesOpen Access

Effects of Dofetilide and EGIS-7229, an Antiarrhythmic Agent Possessing Class III, IV, and IB Activities, on Myocardial Refractoriness in Hyperkalemia, Hypokalemia, and During β-Adrenergic Activation in the Rabbit Papillary Muscle In Vitro

Q: What are the key findings of this study?

EGIS-7229 lengthened the effective refractory period more than dofetilide at 2 Hz stimulation in hypokalemia (P<0.05) and maintained its effect during β-adrenergic stimulation.

View Full Paper

Ask AI

Bookmark

Key result

EGIS-7229 lengthened the effective refractory period more than dofetilide at 2 Hz stimulation in hypokalemia (P<0.05) and maintained its effect during β-adrenergic stimulation.

Why the study?

Does EGIS-7229 improve myocardial refractoriness compared to dofetilide in hypokalemia, hyperkalemia, and during beta-adrenergic activation in rabbit papillary muscles?

Structured PICO

Does EGIS-7229 improve myocardial refractoriness compared to dofetilide in hypokalemia, hyperkalemia, and during beta-adrenergic activation in rabbit papillary muscles?

Population

In vitro study of right ventricular papillary muscles from male New Zealand white rabbits to evaluate the effects of EGIS-7229 and dofetilide on effective refractory period.

Intervention

EGIS-7229 (3 and 10 µM) and dofetilide (30 and 100 nM) applied in vitro

Comparator

Baseline (before drug application) and direct comparison between EGIS-7229 and dofetilide

Outcome

Effective refractory period (ERP) measured in milliseconds using a standard extrastimulus techniquesurrogate

Main Result

p-value: p=<0.05

EGIS-7229 demonstrated superior efficacy in prolonging the effective refractory period compared to dofetilide under hypokalemic conditions and during beta-adrenergic stimulation in a preclinical rabbit model.

Limitations

In vitro animal model, which may not fully translate to human clinical settings
Additional mechanisms for the resistance of ERP lengthening to β-adrenergic stimulation cannot be excluded

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support EGIS-7229 development for hypokalemia-related arrhythmias; leaves open clinical translation from this rabbit model.

Cite This Study

Kovács et al. (2006) studied Normal myocardium (in vitro). EGIS-7229 vs. Dofetilide (30 and 100 nM) was evaluated on Effective refractory period (ERP) prolongation at 2 Hz stimulation rate in hypokalemia (p=<0.05). EGIS-7229 lengthened the effective refractory period more than dofetilide at 2 Hz stimulation in hypokalemia (P<0.05) and maintained its effect during β-adrenergic stimulation.

synapsesocial.com/papers/6a82d837236bcdbab08d597a https://doi.org/10.1254/jphs.fp0051009

View Full Paper

Ask AI

Bookmark

Effects of Dofetilide and EGIS-7229, an Antiarrhythmic Agent Possessing Class III, IV, and IB Activities, on Myocardial Refractoriness in Hyperkalemia, Hypokalemia, and During β-Adrenergic Activation in the Rabbit Papillary Muscle In Vitro

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Effects of Dofetilide and EGIS-7229, an Antiarrhythmic Agent Possessing Class III, IV, and IB Activities, on Myocardial Refractoriness in Hyperkalemia, Hypokalemia, and During β-Adrenergic Activation in the Rabbit Papillary Muscle In Vitro

Structured PICO

Main Result

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider